Allergy creeps forward, hoping rising barrier to entry will repel competition
This article was originally published in Scrip
Executive Summary
Earlier this week, Allergy Therapeutics announced that it had submitted responses to questions raised by regulators in Europe and the US about its Pollinex Quattro allergy immunotherapy products, indicating some degree of progress down the seemingly interminable path towards official registration of these products. But given that the rate-limiting factors in Allergy's attempts to achieve registration tend to relate to regulatory systems rather than issues within Allergy's control, the submission of answers is not a major breakthrough.